Kala-azar - Progress against a neglected disease

New England Journal of Medicine

Volumn 347, Issue 22, 2002, Pages 1793-1794

  Murray, Henry W ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIMONY; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; LEISHMANIA VACCINE; PAROMOMYCIN; STIBOGLUCONATE SODIUM;

BONE MARROW BIOPSY; CELLULAR IMMUNITY; CLINICAL FEATURE; DISEASE TRANSMISSION; DRUG COST; EDITORIAL; ENDEMIC DISEASE; HEALTH CARE COST; HISTORY OF MEDICINE; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; LEISHMANIA DONOVANI; NON INVASIVE MEASUREMENT; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; VECTOR CONTROL; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; ANTIPROTOZOAL AGENTS; ENDEMIC DISEASES; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; PROTOZOAN VACCINES;

EID: 0037191720     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe020133     Document Type: Editorial

References (12)

1. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46.
2. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2:494-501.
3. Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996;124:664-72.
4. Davidson RN. Visceral leishmaniasis in clinical practice. J Infect 1999;39:112-6.
5. Costa CHN, Stewart JM, Gomes RBB, et al. Asymptomatic human carriers of Leishmania chagasi. Am J Trop Med Hyg 2002;66:334-7.
6. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001;45:2185-97.
7. Murray HW, Lu CM, Mauze S, et al. Interleukin 10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002;70:6284-93.
8. Handman E. Leishmaniasis: Current status of vaccine development. Clin Microbiol Rev 2001;14:229-43.
9. Morales MA, Cruz I, Rubio JM, et al. Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. J Infect Dis 2002;185:1533-7.
10. Croft SL, Yardley V. Chemotherapy ofleishmaniasis. Curr Pharm Des 2002;8:319-42.
11. Sundar S, Sahu M, Mehta H, et al. Noninvasive management of Indian visceral leishmaniasis: Clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis 2002;35:581-6.
12. Gavgani ASM, Hodjati MH, Davies CR. Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: A matched-cluster randomised trial. Lancet 2002;360:374-9.